INOZYME PHARMA INC (INZY)
US45790W1080 - Common Stock
Inozyme Pharma to Present at Upcoming Investor Conferences
Inozyme Pharma to Present at Upcoming Investor Conferences
BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company...
RSI Alert: Inozyme Pharma (INZY) Now Oversold
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights
- Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 – - Topline data from...
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701
- INZ-701 was well-tolerated and significantly increased plasma pyrophosphate (PPi) levels in patients with end-stage kidney disease (ESKD) undergoing...
INZY Crosses Below Key Moving Average Level
Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024
BOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company...
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors
BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company...
INZY Crosses Below Key Moving Average Level
Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting
Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference
Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference
BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company...
INZY Stock Earnings: Inozyme Pharma Misses EPS for Q2 2024
INZY stock results show that Inozyme Pharma missed analyst estimates for earnings per share the second quarter of 2024.
INZY Stock Earnings: Inozyme Pharma Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Inozyme Pharma (NASDAQ:INZY) just reported results for the second quarter of 20...
Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights
Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights
Inozyme reported financial results for the second quarter ended June 30, 2024, and provided business highlights....
Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function
- Treatment with INZ-701 shown to prevent intimal proliferation in both ENPP1-deficient and wild-type mice, supporting its potential therapeutic...
INZY Makes Bullish Cross Above Critical Moving Average
Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency
Agency program will support and expedite clinical studies addressing severe unmet need in children with ABCC6 Deficiency
Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency
Agency program will support and expedite clinical studies addressing severe unmet need in children with ABCC6 Deficiency...
Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)
Results from a radiographic study describing skeletal features of pediatric patients with ENPP1 Deficiency will be presented
Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)
Results from a radiographic study describing skeletal features of pediatric patients with ENPP1 Deficiency will be presented...
INZY Makes Bullish Cross Above Critical Moving Average
Inozyme Pharma to Present at the Jefferies Global Healthcare Conference
Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences
BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease...
Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference
Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference
BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease...
INZY Stock Earnings: Inozyme Pharma Misses EPS for Q1 2024
INZY stock results show that Inozyme Pharma missed analyst estimates for earnings per share the first quarter of 2024.
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
Inozyme reported financial results for the first quarter ended March 31, 2024 and provided business highlights....